Typical Burkitt lymphoma is characterized by an IG-MYC translocation and overall low genomic complexity. Clinically Burkitt lymphoma has a favourable prognosis with very few relapses. However, the few patients experiencing disease progression and/or relapse have a dismal outcome. Here we report cytogenetic findings of seven cases of Burkitt lymphoma in which sequential karyotyping was performed at time of diagnosis and/or disease progression/relapse(s). After case selection, karyotype re-review and additional molecular analyses were performed in 6 paediatric cases, treated in Berlin-Frankfurt-Münster-NHL studygroup trials, and one additional adult patient. Moreover, we analysed 18 cases of Burkitt lymphoma from the Mitelman database in which sequential karyotyping was performed. Our findings show secondary karyotypes to have a significant increase in load of cytogenetic aberrations with a mean number of 2, 5 and 8 aberrations for primary, secondary and third investigations. Importantly, this increase in karyotype complexity seemed to result from recurrent secondary chromosomal changes involving mainly trisomy 21, gains of 1q and 7q, losses of 6q, 11q, 13q, and 17p. In addition, our findings indicate a linear clonal evolution to be the predominant way of cytogenetic evolution. Our data may provide a biologic framework for the dismal outcome of progressive and relapsing Burkitt lymphoma.
suMMARY
Typical Burkitt lymphoma is characterized by an IG-MYC translocation and overall low genomic complexity. Clinically Burkitt lymphoma has a favourable prognosis with very few relapses. However, the few patients experiencing disease progression and/or relapse have a dismal outcome. Here we report cytogenetic findings of seven cases of Burkitt lymphoma in which sequential karyotyping was performed at time of diagnosis and/or disease progression/relapse(s). After case selection, karyotype re-review and additional molecular analyses were performed in 6 paediatric cases, treated in Berlin-Frankfurt-Münster-NHL studygroup trials, and one additional adult patient. Moreover, we analysed 18 cases of Burkitt lymphoma from the Mitelman database in which sequential karyotyping was performed. Our findings show secondary karyotypes to have a significant increase in load of cytogenetic aberrations with a mean number of 2, 5 and 8 aberrations for primary, secondary and third investigations. Importantly, this increase in karyotype complexity seemed to result from recurrent secondary chromosomal changes involving mainly trisomy 21, gains of 1q and 7q, losses of 6q, 11q, 13q, and 17p. In addition, our findings indicate a linear clonal evolution to be the predominant way of cytogenetic evolution. Our data may provide a biologic framework for the dismal outcome of progressive and relapsing Burkitt lymphoma.
intRoDuCtion
Burkitt lymphoma (or Burkitt leukaemia / B-AL L3 in case of ≥25% bone marrow involvement) is the most common paediatric B-cell lymphoma and accounts for 1-5% of all lymphomas in adults (Miles et al, 2012 , Burkhardt et al, 2011 , Linch, 2012 . The biologic hallmark of Burkitt lymphoma is the IG-MYC translocation affecting chromosomal region 8q24. This translocation most commonly involves the IGH locus at chromosomal locus 14q32 or less commonly the IGK (2p12) or IGL (22q11) loci and results in deregulated MYC expression by juxtaposing the MYC oncogene to enhancers of one of the three immunoglobulin genes (Aukema et al, 2014 , Klapproth & Wirth, 2010 . In contrast to other lymphomas, the IG-MYC translocation in Burkitt lymphoma is considered a primary disease-initiating event. Burkitt lymphoma has an overall low genomic complexity (Boerma et al, 2009 , Hummel et al, 2006 , Salaverria & Siebert, 2011 , Aukema et al, 2014 , Seegmiller et al, 2010 , Scholtysik et al, 2010 with up to 40% of Burkitt lymphoma lacking cytogenetically detectable secondary chromosomal changes in addition to the IG-MYC translocation (Johansson et al, 1995 , Boerma et al, 2009 , Berger et al, 1989 . Karyotype complexity has been associated with aggressive disease and poor prognosis in various lymphomas including Burkitt lymphoma and other MYC-translocation positive lymphomas (Hummel et al, 2006 , Poirel et al, 2009 , Aukema et al, 2014 , Johansson et al, 1995 , Seegmiller et al, 2010 . With use of aggressive (immuno)chemotherapy regimens high survival rates have been achieved with 5-year cumulative relapse/progression rates of only 11.4% and 16.5% for children and adolescents respectively (Burkhardt et al, 2011) . However, the management of the few patients who do show disease progression and/or relapse of Burkitt lymphoma remains a true challenge as, despite salvage therapies, survival rates in these patients are only as low as 10-30% (Woessmann, 2013) .
Recently there has been made major progress in unravelling the pathogenesis of primary Burkitt lymphoma (Love et al, 2012 , Richter et al, 2012 , Schmitz et al, 2012 . However, still little is known about the underlying genetics of disease progression and relapse. Studies of sequential biopsies in other B-cell neoplasms, particularly follicular lymphoma, have shown different pathways of relapse and progression, e.g. relapses can directly evolve from the previous follicular lymphoma-clone (linear evolution) but also from an earlier tumour precursor shared by both the primary tumour as the relapse (divergent evolution) (Green et al, 2013 , Okosun et al, 2014 , Berglund et al, 2006 , Johnson et al, 2008 
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Chapter 3 Clonal evolution in Burkitt lymphoma al, , Loeffler et al, 2015 . Importantly, several studies have highlighted the biological and prognostic relevance of clonal evolution in lymphoma entities other than Burkitt lymphoma (Jiang et al, 2014 , Loeffler et al, 2015 , Rossi et al, 2014 , Landau et al, 2014 . However, for Burkitt lymphoma few cases with sequential biopsies at diagnosis and relapse/disease progression have yet been published.
We collected and analyzed therefore all cases of Burkitt lymphoma with sequential karyotypes available at our institutions and explored the Mitelman database to investigate the (molecular)cytogenetic characteristics of these lymphomas at diagnosis and in secondary biopsies.
MAteRiAls & MethoDs
Case selection and pathology review: Cases of progressive/relapsing Burkitt lymphoma (hereafter 'relapse') presenting with an IG-MYC translocation in which sequential karyotyping was performed and sufficient material for karyotype review available were retrieved from the files of the Institute of Human Genetics of the Christian Albrecht University Kiel and the Berlin Frankfurt Münster (BFM)-NHL Study Center. Pathology review of the available material (cases 1, 4, 5 and 7) was done by two expert hematopathologists (W.K, I.O.)(Supporting information, Supporting Figure 1 ) resulting in total seven cases entering the study.
(Molecular) Cytogenetics: For all in-house cases, metaphases were R-and/ or G-banded according to standard methods and karyotypes analyzed at the approximately 300-band level. All karyotypes were re-reviewed for this study and described according to the ISCN 2013 nomenclature (E.M.M.P and J.B.) (ISCN, 2013) . For cases with sufficient material available additional molecular cytogenetic analyzes were performed. FISH for MYC was performed with commercially available MYC break-apart-probe (BAP) and MYC-IGH tri-color-dual-fusion probes (all Abbott-Vysis, Downers Grove, IL) as well as with assays for the detection of IGL breaks and MYC-IGL fusions (Hummel et al, 2006 , Martin-Subero et al, 2002 . If possible, 100 well-conserved interphase nuclei were analyzed.
Karyotype complexity score and conversion of karyotypes: Karyotypes were considered complex (complex karyotype, CK) if they had ≥3 aberrations (including IG-MYC) (Havelange et al, 2013) . We also calculated a karyotype complexity score for each patient, taking into account the sum of all numerical and structural chromosomal aberrations. For structural aberrations each abnormality was counted as one event (e.g. "add(1)(q22)" or "t(8;14)(q24;q32)" irrespective of the number of chromosomes involved in the aberration) (Pillai et al, 2013) . For evaluation of numerical and structural chromosomal aberrations karyotypes were converted with the Cydas software package (Hiller et al, 2005) . A full description of the analysis of the cytogenetic data can be found in the Supporting information.
Mitelman database:
To search the published cytogenetic literature for other cases of Burkitt lymphoma with sequential karyotypes available we used the "Mitelman database of chromosome aberrations and gene fusions in cancer" (http:// cgap.nci.nih.gov/chromosomes/mitelman) as comprehensive cytogenetic resource (accessed 18.04.2013) (Mitelman, et al, 2013) . A full description can be found in the Supporting information. 
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Mathematical modelling of timing and nature of the relapses:
The mathematical model is based on a multi-type branching process with proliferation, apoptosis and mutation rate as parameters. Branching processes are a common tool used for the mathematical modelling of cancer progression (Bozic et al, 2010 , Kimmel & Axelrod, 2002 
Results
Seven cases of Burkitt lymphoma with an IG-MYC translocation present in sequential karyotypes fulfilled the inclusion criteria. These included six paediatric patients (median age at diagnosis 9 years, range 4 -13 years), five male and one female, and one adult male patient (44-years at diagnosis) ( Table I, Table   II ). All paediatric patients were treated in population based prospective clinical trials from the NHL-BFM study group. For all patients, karyotypes from at least two time points (diagnosis and/or relapse and at least one sequential sample)
were examined: three paediatric patients could be studied at three time points.
The cases included five initial diagnosis-sequential sample pairs (one sequential sample n=3; two sequential samples n=2) and two patients were studied at time of first relapse and secondary relapse(s). Clinical characteristics of paediatric patients are shown in Table I . All patients had relapsing disease within one year after diagnosis (range 8-30 weeks) and patients 1, 3, 4, 6 and 7 suffered from multiple relapses. All paediatric patients died within two years after diagnosis, often shortly after relapse. The adult patient died within one year after diagnosis due to refractory and progressive disease. Karyotypes and FISH results are displayed in Table I . Six of seven (86%) cases showed a t(8;14)(q24;q32)/MYC-IGH translocation and one (14%) a variant t(8;22)(q24;q11)/MYC-IGL. In all patients the IG-MYC fusion was verified in at least one of the samples by FISH (Table II) .
In the Mitelman database eighteen published cases fulfilled the inclusion criteria (Supporting information / Supporting Table 1 ). Here a t(8;14)/MYC-IGH was seen in 15/18 cases (83%) and a variant light chain translocation in a 3/18 (17%).
Karyotype complexity: A complex karyotype (defined as ≥3 aberrations including the IG-MYC translocation) in initial diagnosis and in sequential samples, respectively, was seen in 0/5 (0%) and 7/7 (100%) in-house patients and in 9/18 (50%) and 13/18 cases (72%) of the Mitelman cohort. We also calculated a complexity score (CS) for the combined in-house and Mitelman cohorts (see Materials & Methods). The complexity score ranged from 1 in samples with only an IG-MYC translocation to 15 in case 6 (Table II) . The mean complexity score was 2, 5 and 8 for primary, secondary and third investigations, respectively (Figure 1 
Clonal evolution:
In all in-house cases we found strong evidence for linear clonal evolution with aberrations present in a (sub)clone at diagnosis also present in sequential karyotypes (in context of newly acquired aberrations) (Table II, clone were not present anymore and overall fewer aberrations were seen. In total 20/25 of the sequential samples showed linear clonal evolution retaining abnormalities (other than the IG-MYC translocation) already present in previous karyotypes in addition to newly acquired aberrations. Of note, at time of initial diagnostic some subclones with chromosomal changes such as trisomies 12 and dup(1q) were already present indicating ongoing evolution (Table II, Supporting   Table I , Supporting Figure 3 ).
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DisCussion
Since the original description by Denis Burkitt and the cloning of MYC as the involved oncogene Burkitt lymphoma has become an important disease model for studying cancer genetics (Boerma et al, 2009 , Miles et al, 2012 , Dalla-Favera et al, 1982 . In contrast to patients at first presentation, patients with progressive and/or relapsing disease have a dismal prognosis. Therefore we aimed to identify the (molecular)cytogenetics changes and characteristics which might be involved in this worsened outcome. All the patients analysed in this study died from the lymphoma, often within one year after initial diagnosis, highlighting the dismal prognosis of these patients. Whereas ≥25% bone marrow involvement, classified as B-AL L3/Burkitt leukaemia, is observed at a considerable lower frequency compared to BL (Patte et al, 2001 , Burkhardt et al, 2005 , in the cases included in the present study 3/5 paediatric patients fulfilled the criteria of B-AL L3.
The findings from the current study, including six paediatric patients from population based prospective clinical trials, showed sequential karyotypes to have a significantly higher, almost linear, increase in load of karyotypic changes. Karyotype complexity has an adverse prognostic impact in MYC-positive lymphomas (Hummel et al, 2006 , Poirel et al, 2009 , Aukema et al, 2014 , Seegmiller et al, 2010 .
However, at initial diagnosis the vast majority of the cases had a simple karyotype with a mean complexity score of 2, which is comparably low to the overall complexity of BL (Boerma et al, 2009) . Moreover, 39% of the cases included in our present study had the IG-MYC translocation as sole karyotypic abnormality, comparable to the lack of secondary chromosomal changes in addition to the IG-MYC translocation found in ≈40% of BL in other studies (Boerma et al, 2009 , Johansson et al, 1995 , Berger et al, 1989 . This means that the initial cytogenetic complexity in our series can not explain the progression and poor outcome in these cases. In line with literature and our mathematical modelling all relapses from our in house cohort occurred within one year after diagnosis (Patte et al, 2001 , Busch et al, 2004 , Atra et al, 2001 , Jourdain et al, 2015 , suggesting "true"
relapse from a malignant clone rather than from a (common) Burkitt lymphoma progenitor cell or the development of a second Burkitt lymphoma (Barriga et al, 1988 , Nguyen et al, 2014 , Kojima et al, 2015 .
In addition to increasing karyotype complexity we observed evidence for linear clonal evolution. Although apparent "loss" of abnormalities occurred in certain cases, this concerned (with exception of three cases with subclones of partial
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Chapter 3 Clonal evolution in Burkitt lymphoma gain of 1q, loss of 18p and trisomy 21) loss of sidelines/subclones containing non-recurrent Burkitt lymphoma aberrations (which could be considered a reflection of MYC induced genomic instability) rather than loss of recurrent secondary chromosomal changes within the main clone. In addition, it cannot be ruled out that in the cases from the Mitelman database (subclonal) aberrations might have remained undetected as we were not able to critically review the karyogram and/ or perform any additional molecular cytogenetic investigations. Moreover, clonal evolution is not limited to sequential biopsies but is also an ongoing phenomenon as some patients harbour several related subclones at the same point in time. What drives the clonal evolution in these cases remains unclear, although several different mechanisms (spontaneous, selection and/or chemotherapy induced) may contribute to this. Intrinsic to conventional cytogenetic analysis, only a limited number of metaphases in our samples were analysed and therefore it is conceivable that, in analogy to the very small TP53 mutated subclones in chronic lymphocytic leukaemia identified by ultra deep-sequencing (Rossi et al, 2014) , also in our cases the dominant and complex clones identified in sequential samples were already present but not detected at diagnosis. If this would be the case, this would argue for both selection and outgrowth of (therapy resistant) subclones after therapy.
The observed pattern of clonal evolution in Burkitt lymphoma seems to differ from that in follicular lymphoma and diffuse large B-cell lymphoma where both linear and early/late divergent evolution have been observed (Berglund et al, 2006 , Green et al, 2013 , Jiang et al, 2014 , Johnson et al, 2008 , Okosun et al, 2014 , Pasqualucci et al, 2014 . This is most likely attributable to the high proliferation rate of Burkitt lymphoma which is by far outnumbering that of follicular lymphoma or diffuse large B-cell lymphoma in most cases. Of note, in follicular lymphoma the assumed precursor cells for divergent clonal evolution is a probably long-lived lymphatic cell carrying the translocation t(14;18)/IGH-BCL2 providing prolonged cell survival and anti-apoptotic protection rather than being per se a strong pro-proliferative cancer driver like the MYC translocation.
Nevertheless next generation sequencing approaches might also in Burkitt lymphoma identify subclonal mutations pointing to derivation from a (more) common progenitor (Green et al, 2013 , Okosun et al, 2014 , Jiang et al, 2014 .
The secondary chromosomal changes observed, 11q aberrations, gain of 1q and 7q, loss of 6q, 13q and 17p are typical secondary Burkitt lymphoma aberrations (Boerma et al, 2009 , Davidsson et al, 2007 , De Souza et al, 2014 , Johansson et al, 1995 , Nelson et al, 2010 , Lones et al, 2004 , Murga Penas et al, 2014 , Onciu et al, 2006 , Poirel et al, 2009 . Although 1q, 7q and 13q aberrations were frequently already present at diagnosis, their incidence was markedly higher in sequential biopsies. Interestingly, not only was the frequency of 1q gains higher in sequential karyotypes, the most frequently gained region of 1q seemed to be different and more proximal localized (1q23~32 in initial diagnostic samples and 1q21~25 in sequential karyotypes). In addition, 11q aberrations (structural aberrations and/or losses), loss of 17p and trisomy 21 were mainly seen in sequential samples, suggesting a role in disease progression. Candidate genes mapping to the regions frequently involved at relapse include ATM (11q22), MLL (11q23), DLEU1 (13q14), TP53 and HIC1 (17p13) (Stocklein et al, 2007 , Meeker et al, 2011 , Scholtysik et al, 2010 , Nelson et al, 2010 . This observed pattern of secondary chromosomal changes parallels the karyotypic evolution from BL cell from the "Forschungshilfe Station Peiper" is greatfully acknowledged.
Authorship and disclosures:
Design of the study and data analysis / interpretation: SMA, PMK, RS and EMMP. Case selection and pathology review: Only cases without constitutional karyotype abnormalities were reviewed and therefore one case with a constitutional abnormality was excluded. Cases representing double-hit lymphoma at diagnosis (defined as chromosomal breakpoints affecting loci 18q21/BCL2, 3q27/BCL6, 9p13 (potentially involving PAX5) (Johnson et al, 2009 , Avet-Loiseau, 2008 , Bertrand et al, 2008 or 11q13/CCND1 in addition to 8q24/MYC) were also excluded (Aukema et al, 2011) . The study was performed in accordance with the guidelines of the institutional review board (IRB) of the Medical Faculty of the Christian-Albrechts-University Kiel (AZ.: D403/05 and 447/10, amendment from 09.03.2010).
Material for pathology review was available in four cases (patients 1, 4, 5, and 7).
A representative example is shown in Supporting Figure S1 .
Karyotype complexity score: For the calculation of the karyotype complexity marker chromosomes were (unless stated otherwise) counted as events. In case of derivative chromosomes resulting from multiple intrachromosomal rearrangements and/or deletions, e.g. der(1)dup(1)(q12q21)hsr(1)(q21) or der(11)del (11) (p12)del(11)(q23) the individual events underlying the formation of a derivative chromosome were scored (e.g. CS = 2). The presence of multiple copies of rearranged chromosomes, e.g. t(8;14)(q24;q32)x2 were considered two events. In case of a given time point cytogenetic studies from different sources were available (e.g. peripheral blood and bone marrow) or (multiple) subclones were present at one time point for one source, one single complexity score was calculated.
Published sequential karyotypes:
We conducted a search in the Mitelman database (Mitelman et al, 2013) using the following cytogenetic algorithm; we searched for cases with 8q24 breakpoints (excluding "double-hit" lymphomas (Aukema et al, 2011) with aberrations affecting loci 18q21/ BCL2, 3q27/BCL6, 9p13/PAX5 and 11q13/ CCND1). Only cases of B-cell lineage (published after mapping of the translocation breakpoints to sub-bands 8q24 by Zhang et al. in 1982 (Zhang et al, 1982 were included in the search and cases needed to have ≥2 or investigations with a t(8;14)(q24;q32), t(8;22)(q24;q11) or t(2;8)(p12;q24)
(representing an IG-MYC translocation). So cases without an IG-MYC translocation in biopsies, e.g. obtained during response evaluation, were not selected.
Cases needed to have Burkitt lymphoma/leukaemia as diagnosis. In addition manual literature searches were performed. In total eighteen cases matching these criteria were identified (Supporting Table I ). Cases in which no consensus or incomplete karyotypes were provided in the original manuscripts (at diagnosis and/or relapse) (Fitzgerald & Morris, 1984 , Abe et al, 1982 , Douglass et al, 1980 , Shikano et al, 1993 , Vazquez-Mazariego et al, 1994 , studies focusing on evolution of patient derived cell lines and long-term cultures, as well as a rare case of unrelated secondary de novo lymphoma (Barriga et al, 1988) were not included.
Conversion of karyotypes and generation of heatmaps:
For evaluation of numerical and structural chromosomal aberrations karyotypes were converted with the Cydas software package (Hiller et al, 2005) To avoid overrepresentation of aberrations, in case multiple sources were present at one time point (e.g. peripheral blood and bone marrow) or when multiple sequential samples were available for one patient (e.g. multiple relapses), a single consensus karyotype in form of composite karyotype was determined. In case no individual regions or bands were provided, e.g. "add(13)(q?)", the aberration was assigned to the whole chromosome arm (e.g. 13q). Generation of heatmaps: for the generation of the heatmaps only recurrent (quantitative) aberrations other than those involving MYC and IG-loci (defined as occurring in ≥3 patients) were included.
Calculation of survival data and time difference between cytogenetic studies:
A time difference in weeks was calculated when exact data were available. Weeks and months (defined as 30 days) were rounded down to whole numbers. In case only months were provided the first day of each month was arbitrarily designated.
Survival was calculated form the time of initial diagnosis. 
Mathematical modeling of timing and nature of relapsing disease:
The nature of relapsing disease was also assessed with a mathematical approach. Our model is based on a time-continuous branching process (Kimmel and Axelrod, 2002 , Haccou et al, 2005 , Antal and Krapivsky, 2011 , Bozic et al, 2010 , Bozic et al, 2013 , Durrett et al, 2010 . We assume two different types of cells, MYC+ precursor cells, which are not affected by therapy, and Burkitt lymphoma cells, which survived cancer therapy. Both types of cells can lead to a relapse, but precursor cells need an additional mutation. For each of the two types, we assume different proliferation and apoptosis rates. As the presumed cell of origin for Burkitt lymphoma is a germinal center dark zone cell (Basso & Dalla-Favera, 2015, Klein & 118 119 Chapter 3 Clonal evolution in Burkitt lymphoma Dalla-Favera, 2008 and cell cycle rates of 6 -12 hours have been reported for centroblasts (Klein & Dalla-Favera, 2008 , Meyer-Hermann et al, 2012 , Radmacher et al, 1998 we assume that the MYC+-precursor cells divide at most every 6 hours, i.e. 4 times per day. Since precursor cells do not lead to a tumor (Müller et al, 1995) and, as in contrast to the t(14;18)/IGH-BCL2, (virtually) no benign neoplasms or lymph nodes with the t(8;14)/MYC-IGH have been described (Kluin, 2014 , Limpens et al, 1991 , Mamessier et al, 2014 , Tellier et al, 2014 , Nagy et al, 2009 ) the apoptosis rate has to be (at least) equal to the division rate, i.e. 4 per day. The division and apoptosis rates for full-blown Burkitt Lymphoma cells are obtained using the empirically de- hours (Woo et al, 1980 , Drexler 2010 . This leads to differences of approximately b -d = 0.7, 0.5 and 0.35. Additionally, from Woo et al., (Woo et al, 1980) Gillespie, 1977) . The remaining lymphoma cell quickly produces a lineage that grows exponentially fast. After less than one month, the population of Burkitt lymphoma cells already reaches about 1 Million cells. Supporting Figure 6 shows the estimated probability for a relapse to occur via a Burkitt lymphoma cell that has survived therapy compared to a relapse via a mutated precursor cell. We notice that the mutation rate has to be enormously high (far exceeding those reported in literature) (Tomasetti et al, 2013) in order for a relapse to happen via a mutated precursor cell. Overall the probability for a relapse to occur via a left-over Burkitt lymphoma cell is greater than about 80%.
Even for a rather slow doubling time of 48 hours, a high cell loss factor of 0.667
(red line in (c)), and an enormously high mutation rate of 0.1 the probability for a Burkitt lymphoma relapse is still approximately 75%. Already for a mutation rate of 10 -5 the probability for a relapse via a precursor cell is virtually 0%. Therefore, testing for even lower mutation rates is not necessary here.
To stress the robustness of the probability of a relapse via a left-over Burkitt lymphoma cell, we have run additional simulations with parameters that reflect an even greater advantage for precursor cells compared to the already conservative set of parameters described above. In particular we have used a proliferation and (Boerma et al, 2004 , Bianconi et al, 2013 , Harrison, 1962 , Busch et al, 2004 , Kuczmarski et al, 2002 , Kliegman et al, 2011 ).
Supporting Figure 7 shows that according to our model relapses from left-over
121
Chapter 3 Clonal evolution in Burkitt lymphoma
Burkitt lymphoma cells need a little over a month to occur with the parameters stated in the caption. Also relapses from a precursor cell seem to occur very quickly. However, the mutation rate of is chosen to be very high. With a lower mutation rate we would see even less relapses occurring via a precursor cell, because relapses via a left-over Burkitt lymphoma cell are much faster. To check the timing of relapses occurring via a mutated precursor cell, we therefore set the number of left-over Burkitt lymphoma cells to one and use a more realistic mutation rate. Setting the number of left-over Burkitt lymphoma cells to one leads to a higher of probability for this lineage to die out by stochastic effects, which leaves time for the precursor lineage to produce a relapse. The timing for these parameters is shown in Supporting Figure 8 . 
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Chapter 3 Clonal evolution in Burkitt lymphoma supporting figure 3: Pedigrees of clonal evolution of patient 1 (A) and M8 (B). Different subclones present in the same investigation, indicating ongoing clonal evolution, are shown in boxes (solid lines). The box with the dashed lines in (B) represents the assumed events which have given rise to the clones found in the karyotype at diagnosis. (A) Patient 1 was studied at time of diagnosis, secondary and third relapse with karyotype complexity scores of 1, 9 and 11 respectively. (B) Patient M8 studied was studied at diagnosis and relapse. While at relapse two of the sidelines/subclones present at initial diagnosis (containing a der(X)t(X;1)(p11;q23) and a der(X)t(X;1)(p11;q23) + marker chromosome) were not detected anymore, there was clonal evolution of the stem/mainline (with an inverted duplication of 1q, dup(1q) (q32q23) ) which acquired an additional chromosome 7 and additional partial gain of chromosome 1q. Both the stem/mainline and the subclones/sidelines had breakpoints involving 1q23, potentially targeting the same chromosomal region or gene important for progression.
Figure modified from Aukema & Siebert, (Aukema & Siebert, 2012) . Pr= progressive Burkitt lymphoma. 
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Chapter 3 Clonal evolution in Burkitt lymphoma supporting figure 6: The estimated probability that a relapse happens via a Burkitt lymphoma cell that has survived therapy and not via precursor cells. In (a)-(c) the initial numbers of cells for precursor and left-over Burkitt lymphoma cells are 10. For a relapse to happen via a precursor cell, the mutation rate needs to be very high. Even for a mutation rate of 0.1 the probability is approximately 80% for a relapse to happen via a left-over Burkitt lymphoma cell. With a high doubling time and a high cell loss factor (d/b) (red line in (c)) that probability drops to approximately 75%. In (d)-(f) the initial number of cells for precursor cells is increased to 100. Further, the rate for proliferation and apoptosis is increased to 2 hours. Also for these extreme parameters for Burkitt lymphoma cell, our model suggests a probability of a relapse via a Burkitt lymphoma cell of 100% for a mutation rate of or slower.
supporting figure 7:
The distributions of relapse times after therapy. In both histograms we have a doubling time of 33.27 (i.e. ) hours and a cell loss factor of 0.5. The mutation rate is . Left: The precursor cells divide and die with rate 6 hours and initially there are 10 leftover Burkitt lymphoma cells and 10 precursor cells. There are no relapses happening via a mutated precursor cell. Right: The precursor cells proliferate and die with rate 2 hours and there are 100 precursor cells present initially. There are some relapses occurring via a newly founded Burkitt lymphoma lineage (red bars). Relapses via mutated precursor cells tend to take slightly more time on average to happen compared relapses via a left-over Burkitt lymphoma cell.
supporting figure 8: The distributions of relapse times after therapy for a different set of parameters. As in Supporting Figure 7 , a doubling time of 33.27 (i.e. ) hours and a cell loss factor of 0.5 are assumed. The initial number of cells for left over Burkitt lymphoma cells is only one and for precursor cells it is 1000. The mutation rate is set to . Precursor cells divide and die every 6 hours. X-axis displays time in days after end of therapy, Y-axis number of relapses (logarithmic scale) While the relapses occurring from a left over Burkitt lymphoma cell need on average approximately 38 days, the relapses occurring via a mutated precursor cell need much longer, approximately 200 days on average. A slower turnover rate and a smaller mutation rate would lead to an even later timing of the relapses via precursor cell. 
127
